Basic Information
Camcevi
Regulatory Information
EMEA/H/C/005034
May 24, 2022
March 24, 2022
5
April 3, 2025
Company Information
Spain
Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona
ACCORD HEALTHCARE SL
Active Substances Detail
leuprorelin mesilate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Overview Summary
Camcevi is a medicine used in adult men for the treatment of advanced prostate cancer that is ‘hormone-dependent’, meaning that it responds to treatments that lower the level of the hormone testosterone. Camcevi is also used in combination with radiotherapy to treat locally advanced hormone-dependent prostate cancer and high-risk localised prostate cancer (this means that the cancer is likely to spread beyond the prostate gland to nearby tissues and become ‘locally advanced’). Camcevi is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance but has a different formulation. The reference medicine for Camcevi is Eligard. Camcevi is available as a ready-to-use medicine in contrast with Eligard, which requires pre-mixing before it can be given to the patient. The active substance in Camcevi is leuprorelin.